Warren Pharmaceuticals publishes results of preclinical evaluation
Warren Pharmaceuticals has synthesized molecules exhibiting only tissue-protective effects of EPO, with no impact on the classical EPO receptor. These compounds show promise in treating various diseases including stroke, spinal cord compression, diabetic neuropathy, multiple sclerosis, and congestive heart failure.